Evidence map›Paper›PMID 41257976›Full record

ArticleJournal of pharmaceutical health care and sciences2025

Pharmacist follow-up of patients prescribed nirmatrelvir/ritonavir: a single-center retrospective analysis.

Ayako Shigeno, Yasukata Ohashi, Ryosuke Masui, Ayako Kiryu, Koji Nagashima, Hirotake Ohashi, Keisuke Seto, Junichi Masuda, Katsuji Teruya, Mugen Ujiie and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pharmaceutical health care and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ayako ShigenoDepartment of Pharmacy, National Hospital Organization Tokyo Medical Center, 2-5-1 Higashigaoka, Meguro-ku, Tokyo, 152-8902, Japan. sgnayk.mrahp@gmail.com.
Yasukata OhashiDepartment of Pharmacy, National Center for Global Health and Medicine, Japan Institute for Health Security, 1-21-1 Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan.
Ryosuke MasuiDepartment of Pharmacy, National Center for Global Health and Medicine, Japan Institute for Health Security, 1-21-1 Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan.
Ayako KiryuDepartment of Pharmacy, National Center for Global Health and Medicine, Japan Institute for Health Security, 1-21-1 Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan.
Koji NagashimaDepartment of Pharmacy, National Center for Global Health and Medicine, Japan Institute for Health Security, 1-21-1 Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan.
Hirotake OhashiDepartment of Pharmacy, National Center for Global Health and Medicine, Japan Institute for Health Security, 1-21-1 Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan.
Keisuke SetoDepartment of Pharmacy, National Center for Global Health and Medicine, Japan Institute for Health Security, 1-21-1 Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan.
Junichi MasudaDepartment of Pharmacy, National Center for Global Health and Medicine, Japan Institute for Health Security, 1-21-1 Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan.
Katsuji TeruyaAIDS Clinical Center, National Center for Global Health and Medicine, Japan Institute for Health Security, 1-21-1 Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan.
Mugen UjiieDisease Control and Prevention Center, National Center for Global Health and Medicine, Japan Institute for Health Security, 1-21-1 Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan.
Norio OhmagariDisease Control and Prevention Center, National Center for Global Health and Medicine, Japan Institute for Health Security, 1-21-1 Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan.
Takahiro NishimuraDepartment of Pharmacy, National Center for Global Health and Medicine, Japan Institute for Health Security, 1-21-1 Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNirmatrelvir/ritonavir (NMV/r), a drug used to treat coronavirus disease 2019, has raised concerns about potential drug-drug interactions with concomitant medications due to cytochrome P450 3 A inhibition. However, limited data exist on its use alongside concomitant medications in clinical practice. METHODS AND

resultsIn this study, we conducted a retrospective survey using electronic medical records of 32 outpatients whose physicians instructed them to temporarily withdraw some of their regular medications. Medication status and adherence with instructions for the temporary withdrawal of concomitant medications were assessed via telephone. The results showed that three of the 32 patients (9%) took NMV/r contrary to their physician’s instructions, two of whom misused the dosage and one who self-interrupted the treatment. Additionally, 16 patients (50%) did not follow instructions to discontinue their regular medication. Beyond NMV/r adherence, potential post-prescription issues were identified, such as forgetting to resume regular medications or discontinuing medications at the patient’s discretion.

conclusionPost-prescription pharmacist follow-ups may improve adherence to NMV/r and support the safe management of regular medications. Future studies are needed to optimize NMV/r use in clinical practice.

Indexed as

COVID-19Cytochrome P450Drug-drug interactionsNirmatrelvir/Ritonavir

Identifiers

PMID41257976
PMCPMC12628816

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.